Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01684020
Recruitment Status : Completed
First Posted : September 12, 2012
Last Update Posted : February 8, 2019
Sponsor:
Collaborator:
Baxter Healthcare Corporation
Information provided by (Responsible Party):
Steven H. Dayan, DeNova Research

Brief Summary:
Rhinoplasty (nasal reconstruction i.e. "a nose job") is a surgical procedure performed on the nose to correct a medical problem or change the appearance of the nose. During the healing process, swelling and/or bruising is likely to occur. A drug called ARTISS Fibrin Sealant may or may not lessen these effects. This study is looking to see the effects of ARTISS on adhering tissue and improving wound healing in an external rhinoplasty. The purpose of this study is to evaluate the safety and effectiveness of rhinoplasty using ARTISS compared to rhinoplasty without using ARTISS in patients undergoing rhinoplasty performed through an external approach.

Condition or disease Intervention/treatment Phase
Subjects Requesting and Requiring an Open Rhinoplasty Biological: ARTISS human fibrin sealant Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Double-Blinded, Randomized Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty
Actual Study Start Date : November 28, 2012
Actual Primary Completion Date : April 26, 2016
Actual Study Completion Date : April 26, 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Raplixa

Arm Intervention/treatment
Experimental: ARTISS Human Fibrin Sealant
Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.
Biological: ARTISS human fibrin sealant
No Intervention: Standard of Care
Fixation of the skin flap created during external rhinoplasty will use the standard of care



Primary Outcome Measures :
  1. Efficacy [ Time Frame: 4 weeks post-surgery ]
    Edema [(none, mild, moderate, severe)].

  2. The primary safety endpoint is the incidence of AEs. [ Time Frame: 6 months post surgery ]
    Safety will be assessed by the incidence of AEs throughout the study period as documented by clinician observations at study visits and in a 30-day subject diary.


Secondary Outcome Measures :
  1. Severity of Edema [ Time Frame: 1 day, 1 week, 4 weeks and 6 months ]
    Edema will be determined by a live assessment at 1 day, 1 week, 4 weeks and 6 months following surgery using a four-point categorical edema scale [none, mild, moderate, severe)].

  2. Blinded-assessment of satisfaction [ Time Frame: 6 months post surgery ]
    A non-treating blinded evaluator will assess satisfaction with a four-point categorical satisfaction scale [unsatisfied, satisfied, very satisfied, highly satisfied)] of subject's grafts using photographs from baseline, 1 month, 3 months, 6 months, and 12 months and will consist of a blinded evaluation in which the physician is aware of the type of graft, but unaware of plating status or the specific grafting site.

  3. Objective Ecchymosis Evaluation [ Time Frame: 1 day, 1 week, 4 weeks and 6 months following surgery ]
    The surface area and color of ecchymosis will be evaluated using Mirror Software and Vectra 3D photography at 1 day, 1 week, 4 weeks and 6 months following surgery.

  4. Subjective Ecchymosis Evaluation [ Time Frame: 1 day, 1 week, 4 weeks and 6 months following surgery ]
    Ecchymosis will be determined by a live assessment at 1 day, 1 week, 4 weeks and 6 months following surgery using a six-point categorical edema scale

  5. Number of Participants with Adverse Events [ Time Frame: Day 30 ]
    Subjects will complete a 30-day diary documenting adverse events such as erythema, pain, tenderness, firmness, swelling, lumps/bumps, bruising, itching and numbness.

  6. Subject Downtime Questionnaire [ Time Frame: 1 day, 1 week, 4 weeks and 6 months following surgery ]
    Subject downtime will be determined using a questionnaire at 1 day, 1 week, 4 weeks and 6 months following surgery. Responders are defined as those subjects experiencing little to no downtime.

  7. HPSS Assessment [ Time Frame: 1 week, 4 weeks and 6 months following surgery ]
    Changes in subject self-esteem will be determined by subject completion of the Heatherton & Polivy State Self-Esteem (HPSS) Scale at 1 week, 4 weeks and 6 months following surgery

  8. Ease of Use [ Time Frame: Immediately Post Surgery ]
    Ease of use will be determined by the treating investigator using a 10 cm Visual Analog Scale (VAS) to demonstrate technical ease.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and females between 18 and 65 years of age.
  2. Subjects requesting primary rhinoplasty and requiring an external approach.
  3. Subjects willing to undergo treatment with fibrin sealant.
  4. Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
  5. Willingness and ability to comply with the PI's standard preoperative and postoperative rhinoplasty instructions.
  6. Subjects of childbearing potential must have a negative urine pregnancy test result at Visit 1 and be willing able to use an acceptable method of birth control (e.g., barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following is documented on the medical history:

    • postmenopausal for at least 12 months prior to study drug administration
    • without a uterus and/or both ovaries
    • has had a bilateral tubal ligation for at least 6 months prior to study drug administration.
    • absence of an other physical condition according to the PI's discretion
  7. Willingness and ability to provide written photo consent and adherence to photography procedures (i.e., removal of jewelry and makeup).
  8. Willingness and ability to provide written informed consent prior to performance of any study related procedure.

Exclusion Criteria:

  1. Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a reliable form of birth control.
  2. Subjects who are planning a concurrent facial surgery during the operation (eg forehead plasty, blepharoplasty, rhinoplasty, buccal fat removal, any filler injections including fat injections, lip augmentation, skin resurfacing procedures etc.).
  3. Subjects with a previous history of rhinoplasty.
  4. Subjects with a current history of smoking.
  5. Subjects with a previous history of a bleeding or coagulation disorder .
  6. Subject with a previous history of a vascular disorder, cardiovascular disease, and/or uncontrolled hypertension.
  7. Subjects a previous history of diabetes mellitus with glycosylated hemoglobin (HbA1c) > 7.
  8. Subjects undergoing active treatment for a malignancy.
  9. Subjects with a previous history of has a connective tissue disorder.
  10. Subjects with active or chronic skin disorder.
  11. Subjects with a previous history of Bell's palsy.
  12. Subjects with a previous history of pathologically or pharmacologically induced immune deficiency.
  13. Subjects who have received chronic treatment with immunosuppressive drugs, systemic corticosteroids, or other chronic treatments within 30 days prior to the surgery.
  14. Subjects with a known sensitivity to components of FS VH S/D 4 s-apr.
  15. Subjects with a previous history of healing complications following previous surgeries (eg, hypertrophic scarring).
  16. Subjects with a significant systemic illness or illness localized to the areas of treatment.
  17. Subjects with previous history of nasal implants.
  18. Subjects with previous or current history of nasal infections.
  19. Subjects who have history of blood thinners (aspirin, ibuprofen, naprosyn, herbal supplements, Vitamin E) within the two weeks prior to surgery.
  20. Subjects who have smoked within the two weeks prior to surgery.
  21. Subjects who have had alcohol or illicit drugs one week prior to surgery.
  22. Subjects who have eaten or drank anything after midnight the night prior to surgery.
  23. Subjects with current history of chronic drug or alcohol abuse.
  24. Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study medication.
  25. Subjects who anticipate the need for surgery, other than the study procedure, or overnight hospitalization during the study.
  26. Subjects who, in the Investigator's opinion, have a history of poor cooperation, non compliance with medical treatment or unreliability.
  27. Subject has participated in another clinical study involving an investigational product/device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational product/device during the course of this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01684020


Locations
Layout table for location information
United States, Illinois
DeNova Research
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
DeNova Research
Baxter Healthcare Corporation
Investigators
Layout table for investigator information
Principal Investigator: Steven H Dayan, MD DeNova Research

Additional Information:
Layout table for additonal information
Responsible Party: Steven H. Dayan, Medical Director, DeNova Research
ClinicalTrials.gov Identifier: NCT01684020    
Other Study ID Numbers: ART-RHI-12
First Posted: September 12, 2012    Key Record Dates
Last Update Posted: February 8, 2019
Last Verified: February 2019
Keywords provided by Steven H. Dayan, DeNova Research:
rhinoplasty
external rhinoplasty
open rhinoplasty
nose job
Additional relevant MeSH terms:
Layout table for MeSH terms
Fibrin Tissue Adhesive
Hemostatics
Coagulants